- Zacks•3 days ago
Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.
- Motley Fool•3 days ago
This isn't Marathon Pharmaceuticals' first rodeo when it comes to questionable pricing practices.
- TheStreet.com•3 days ago
Astrazeneca stock rose Friday after the company said that its Lynparza drug fared well in clinical trials of its effectiveness as a breast cancer treatment.
VRX : Summary for Valeant Pharmaceuticals Interna - Yahoo Finance
Valeant Pharmaceuticals International, Inc. (VRX)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||15.82 - 16.18|
|52 Week Range||13.00 - 86.55|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.44|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|